Puma Biotechnology, Inc.

PBYI Healthcare Biotechnology

Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

9.83 0.69 −6.56%
Market cap
$543.0M
P/E
18.2×
Fwd P/E
24.2×
Dividend yield
—
F-score
8/9
Altman Z
−4.16
Beneish M
−2.06
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

7 8 7 7
ROE
39.69% 27.97% 21.62% 21.97%
ROA
17.46% 14.48% 12.54% 13.78%
ROIC
39.95% 43.78% 51.10% 42.61%
Return on Tangible Assets
60.46% 38.12% 29.50% 28.02%
Average Days of Receivables
57.79 85.75 42.30 53.76
Free Cash Flow per Share
0.85 0.83 1.05 0.81
Free Cash Flow
42.87 41.73 53.61 41.15
Other line items

Show all line items

Columns are period end dates